Abstract: This disclosure is directed to a process for producing a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that is water insoluble or poorly water soluble. The polymer is water soluble and comprises at least one first terminal group modified with H (H) or a hydrophobic moiety (C) and a second terminal group modified with a hydrophilic moiety. The polymer can be a modified symmetrically or asymmetrically branched polymers. This disclosure is further directed to a method for producing a polymer having a pre-defined H/C ratio.

Abstract: This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a polymer-drug nanoaggregate having a polymer and at least one bioactive agent that is water insoluble or poorly water soluble. The polymer is water soluble and comprises at least one first terminal group modified with H or a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. This disclosure is also directed to a method for treating or preventing a disease including one or more immune disorders, infectious diseases and cancers using the pharmaceutical composition disclosed herein. The pharmaceutical composition can be a vaccine or an adjuvant for a vaccine.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclitaxel and derivatives thereof, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: A device and method for the rapid on-site detection of inhibitors of enzymes, such as, acetylcholinesterase is described where the device contains 2 reaction zones containing a reporter enzyme substrate. One reaction zone is for the test sample while the other is for an onboard negative control. Sample and control fluids are preincubated with the enzyme in separate reaction containers, then an aliquot of each reaction mixture is added to designated reaction zones on the test device. A purpose-built reader or an illuminating device, such as, containing an incandescent light source, a diode, a UV light source or any other illumination source that is suitable for the reporter or mere visualization is used to determine the level of reporter.

Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: A device and method for the rapid on-site detection of inhibitors of enzymes, such as acetylcholinesterase, is described wherein the device contains all reagents added to a sample pad containing dried releasable enzyme creating a reaction mixture wherein inhibitor deactivates the enzyme, while said reaction mixture travels via a longitudinal membrane to a distal porous pad containing a substrate for the enzyme. The reaction of the enzyme and the substrate results in a product that can generate a measurable signal such as color, fluorescence or luminescence to serve as a reporter. Signal that is generated at this reaction zone is inversely proportional to inhibitor concentration in the test sample. A device containing two such strips, one for a test sample, the other for a negative control fluid as an onboard comparator is described.

Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.

Abstract: Modified branched polymers are combined with bioactive agents which are one member of a binding pair for use in an assay.

Abstract: Assays for detecting antibodies to pharmaceutical preparations, food allergens and environmental allergens are described.

Abstract: Compositions comprising an oxazoline polymer and optional linkers to carry a variety of molecules.

Abstract: Incorporation of modified branched polymers in one or more components of assays enhances sensitivity, specificity or both, providing powerful point of use tests.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: Incorporation of modified branched polymers in one or more components of assays enhances sensitivity, specificity or both, providing powerful point of use tests.

Abstract: A conjugate of a modified randomly branched asymmetric polymer without a core and a member of a binding pair is described. The modified randomly branched asymmetric polymer can contain chain branches, terminal branches or both. The modified randomly branched asymmetric polymer can contain random asymmetric branches or random asymmetric junctions. The binding pair can be an antibody, antigen or a ligand.

Abstract: A conjugate of a modified randomly branched asymmetric polymer without a core and a member of a binding pair is described. The modified randomly branched asymmetric polymer can contain chain branches, terminal branches or both. The modified randomly branched asymmetric polymer can contain random asymmetric branches or random asymmetric junctions. The binding pair can be an antibody, antigen or a ligand. The conjugate includes a drug.

Abstract: Modified branched polymers are combined with bioactive agents which are one member of a binding pair for use in an assay.